Grade @ or @ adverse events that differed significantly between the two groups included nausea ( eight -LSB- @ % -RSB- vs one -LSB- < @ % -RSB- ) , vomiting ( @ -LSB- @ % -RSB- vs one -LSB- < @ % -RSB- ) , musculoskeletal pain ( none vs ten -LSB- @ % -RSB- ) , anaemia ( @ -LSB- @ % -RSB- vs six -LSB- @ % -RSB- ) , and thrombocytopenia ( @ -LSB- @ % -RSB- vs three -LSB- @ % -RSB- ) , for the cisplatin plus gemcitabine compared with the paclitaxel plus gemcitabine groups , respectively .